GlaxoSmithKline plc, introduces BLENREP a first-in-class anti-BCMA (B-cell maturation antigen) therapy for the treatment of adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent.
BLENREP is an antibody drug conjugate comprising a humanised anti-B Cell Maturation Antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent auristatin F via non-cleavable linker.
BLENREP has the ability to transform the treatment of patients with relapsed or refractory myeloma who have very few treatment options available in today’s world. On the other hand, due to the lack of treatment options available in the market, patients with this disease are often retreated with drugs.
Multiple myeloma is the second most treatable but not curable type of blood cancer among the people of US. It is estimated that more than 32,000 people are diagnosed with multiple myeloma and nearly 13,000 people die from the disease in this country
US Food and Drug Administration (FDA) has approved BLENREP (belantamabmafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor and an immunomodulatory agent.
